

Docket No. 200488US0CONT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Junji HAMURO, et al.

SERIAL NO: 09 731,830

GAU: 1653

FILED: December 8, 2000

EXAMINER: C. Kam

RCE FILED: Herewith

FOR: IMMUNOMODULATOR

RECEIVED
JUL 14 2003
TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- ☒ The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- ☐ Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present application. A copy of the patent(s), together with a copy of the claims and drawings of the pending application(s) is attached along with PTO 1449.
- ☐ A check is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 05 03)

Norman F. Oblon
Registration No. 24,618

James J. Kelly, Ph.D.
Registration No. 41,504

JUL 09 2003

SHEET 1 OF 1

Form PTO 1449
(Modified)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY DOCKET NO.
200488US0CONTSERIAL NO.
09/731,830

LIST OF REFERENCES CITED BY APPLICANT

APPLICANT
Junji HAMURO, et al.FILING DATE
December 8, 2000GROUP
1653

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA	5,541,162	07/30/96	OHMORI et al.			
	AB	5,804,582	09/08/98	ANDERSSON et al.			
	AC	5,766,873	06/16/98	NOBLE et al.			
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AO	0 715 853 A1	06/12/96	EUROPEAN		
	AP	0 501 641 A1	09/02/92	EUROPEAN		
	AQ	WO 91/18594	12/12/91	WIPO		
	AR					
	AS					
	AT					
	AU					
	AV					

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

	AW	TSUYUKI et al., Possible Availability of N-Acetylcysteine as an Adjunct to Cytokine Therapy for Hepatocellular Carcinoma, Clinical Immunology and Immunopathology, Vol. 88, No. 2, August, pp. 192-198, 1998, Article No. II984574.				
	AX	PETERSON et al., Glutathione levels in antigen-presenting cells modulate Th1 versus Th2 response patterns, Proc. Natl. Acad. Scie. USA, Vol. 95, pp. 3071-3076, March 1998, Immunology.				
	AY	SATO et al., Antioxidants Inhibit Tumor Necrosis Factor- α Mediated Stimulation of Interleukin-8, Monocyte Chemoattractant Protein-1, and Collagenase Expression in Cultured Human Synovial Cells, The Journal of Rheumatology 1996, 23:3, pp. 432-438.				
	AZ	RUFFMAN et al., GSH Rescue by N-Acetylcysteine, Klin Wochenschr (1991) 69:857-862, pp. 857-862.				

☐ Additional References sheet(s) attached

Examiner

Date Considered

*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

JUL 14 2003

TECH CENTER 1600/2300